Research

Hormonal

Inhibition of mTOR by rapamycin exacerbates metabolic dysfunction in type 2 diabetes by preventing beta-cell adaptation, inducing beta-cell apoptosis, and increasing insulin resistance.

Do not use mTOR inhibitors like rapamycin to treat type 2 diabetes. While these drugs may improve insulin sensitivity in muscle, they destroy pancreatic beta-cells and prevent the pancreas from adapting to high blood sugar, leading to severe worsening of diabetes.

GoodRefutesHIGH confidence
Rapamycin induces fulminant diabetes by increasing insulin resistance and reducing beta-cell function and mass. These findings emphasize the essential role of mTOR/S6K1 in orchestrating beta-cell adaptation to hyperglycemia in type 2 diabetes. It is likely that treatments based on mTOR inhibition will cause exacerbation of diabetes.
Merav Fraenkel et al. · Diabetes · 2008

Why this rating

Rigorous in vivo animal model with clear mechanistic pathways, though not directly translatable to human clinical trials without further validation.

Source

mTOR Inhibition by Rapamycin Prevents β-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes

Merav Fraenkel et al. · Diabetes · 2008

DOI 10.2337/db07-0922

mechanism_onlyCited 381×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →